An an experienced Corporate Director and CEO, Doug has chaired the board of a NASDAQ-listed company. Part of his role as a CEO for the past 12 years, Doug had built and turned around 3 pharmaceutical companies. During his 30 years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, and has completed 15 corporate acquisitions across three continents. Doug was also able to raise $4 billion of both public and private capitals.
Investor interest in the potential of psychedelics to provide improved therapies for mental health disorders is growing rapidly and we are delighted to be among the companies included in the Horizons Psychedelic Stock Index ETF.9 February 2021